Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted FCF Margin of 1257.09% for Q1 2026, down 993.68% on a QoQ basis from 114.94% in Q4 2025, and down 34974.0% year-over-year from N/an in Q1 2025.
Recursion Pharmaceuticals (RXRX) FCF Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' FCF Margin history runs 7 years deep, the most recent figure standing at 1257.09% for Q1 2026.
- Quarterly FCF Margin fell 34974.0% year-over-year to 1257.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 480.93% (up 18424.0% YoY) and the FY2025 annual result came in at 497.86%, up 13585.0% from the prior year.
- FCF Margin was 1257.09% for Q1 2026 at Recursion Pharmaceuticals, down from 114.94% in the prior quarter.
- Across five years, FCF Margin topped out at 1369.7% in Q1 2022 and bottomed at 2567.71% in Q4 2024.
- A 5-year average of 707.72% and a median of 646.87% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 259765 bps — and 2025, when it slumped 209121 bps.
- Recursion Pharmaceuticals' FCF Margin stood at 308.91% in 2022, then tumbled by 156 bps to 789.94% in 2023, then sank by 225 bps to 2567.71% in 2024, then surged by 96 bps to 114.94% in 2025, then plunged by 994 bps to 1257.09% in 2026.
- Business Quant data shows RXRX's FCF Margin at 1257.09% in Q1 2026, 114.94% in Q4 2025, and 2363.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -1,257.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,257.09% |
| Dec 31, 2025 | -114.94% |
| Sep 30, 2025 | -2,363.71% |
| Jun 30, 2025 | -389.37% |
| Mar 31, 2025 | -907.35% |
| Dec 31, 2024 | -2,567.71% |
| Sep 30, 2024 | -272.50% |
| Jun 30, 2024 | -527.95% |
| Mar 31, 2024 | -789.86% |
| Dec 31, 2023 | -789.94% |
| Sep 30, 2023 | -692.24% |
| Jun 30, 2023 | -565.47% |
| Mar 31, 2023 | -646.87% |
| Dec 31, 2022 | -308.91% |
| Sep 30, 2022 | -406.23% |
| Jun 30, 2022 | -800.82% |
| Mar 31, 2022 | 1,369.70% |
| Dec 31, 2021 | -2,590.68% |
| Sep 30, 2021 | -1,687.21% |
| Jun 30, 2021 | -2,298.00% |